CMA 200
Alternative Names: CMA-200Latest Information Update: 31 Mar 2023
At a glance
- Originator Life Biosciences
- Class Antidementias; Eye disorder therapies; Small molecules
- Mechanism of Action Autophagy stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Alzheimer's disease; Neurodegenerative disorders; Retinal disorders
Most Recent Events
- 21 Feb 2023 Discontinued - Preclinical for Retinal disorders in USA (unspecified route)
- 06 Sep 2022 Discontinued - Preclinical for Alzheimer's disease in USA (PO) (Life Bioscience pipeline, September 2022)
- 06 Sep 2022 Discontinued - Preclinical for Neurodegenerative disorders in USA (PO) (Life Bioscience pipeline, September 2022)